The fact that exposure to the PCAIs diminishes the levels of the fascin protein, and our previous findings that the PCAIs suppress the number of filopodia per cell [18] points to a clinical potential of the PCAIs in the treatment of metastatic non-small cell lung cancer. The gene discussed is FSCN1; the disease is non-small cell lung carcinoma.